Citation Impact
Citing Papers
14C-labelled glucose turnover in New Zealand soils
1999
Lineage-Specific Changes in Biomarkers in Great Apes and Humans
2015 StandoutNobel
Evaluation of aspirin metabolites as inhibitors of hypoxia-inducible factor hydroxylases
2008 StandoutNobel
The nitrate–nitrite–nitric oxide pathway in physiology and therapeutics
2008 Standout
Characterization of Human Liver Enzymes Involved in the Biotransformation of Boceprevir, a Hepatitis C Virus Protease Inhibitor
2010
Heparin and Low-Molecular-Weight Heparin Mechanisms of Action, Pharmacokinetics, Dosing, Monitoring, Efficacy, and Safety
2001 Standout
Relation between Renal Dysfunction and Cardiovascular Outcomes after Myocardial Infarction
2004 Standout
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention
2011 Standout
Cytochrome P450: taming a wild type enzyme
2011 StandoutNobel
Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy
2007
Posaconazole or Fluconazole for Prophylaxis in Severe Graft-versus-Host Disease
2007 Standout
Has the era of individualised medicine arrived for antifungals? A review of antifungal pharmacogenomics
2011
Quantitative analysis of complex protein mixtures using isotope-coded affinity tags
1999 Standout
Perioperative Management of Antithrombotic Therapy
2012 Standout
Microemulsion-based media as novel drug delivery systems
2000 Standout
Clinical Relevance of the Pharmacokinetic Interactions of Azole Antifungal Drugs with Other Coadministered Agents
2009
New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays
2010 Standout
Nitrite is a signaling molecule and regulator of gene expression in mammalian tissues
2005
Pharmacokinetic aspects of biotechnology products
2004
Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia
2002
A highly sensitive fluorogenic probe for cytochrome P450 activity in live cells
2008
Solid lipid nanoparticles Production, characterization and applications
2001 Standout
Quantitative high‐throughput analysis of drugs in biological matrices by mass spectrometry
2003
Chronobiology and chronotherapy of allergic rhinitis and bronchial asthma
2007
Posaconazole: clinical pharmacology and potential for management of fungal infections
2005
2007 Guidelines for the Management of Arterial Hypertension
2007 Standout
Comparative Pharmacology of Newer Progestogens
1996
A sensitive liquid chromatography and mass spectrometry method for the determination of posaconazole in human plasma
2006
Epidemiology and Outcome of Zygomycosis: A Review of 929 Reported Cases
2005 Standout
Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs
2007 Standout
Mould-active azoles: pharmacokinetics, drug interactions in neutropenic patients
2007
Platelet Activation and Atherothrombosis
2007 Standout
A Human Monoclonal Antibody Targeting Scavenger Receptor Class B Type I Precludes Hepatitis C Virus Infection and Viral Spread In Vitro and In Vivo
2011 StandoutNobel
Inactivating Mutations in NPC1L1 and Protection from Coronary Heart Disease
2014
Antiplatelet Drugs
2008
Factors Influencing the Magnitude and Clinical Significance of Drug Interactions Between Azole Antifungals and Select Immunosuppressants
2006
Circadian control of the immune system
2013 Standout
Prevention of Venous Thromboembolism
2004 Standout
New Therapies for Reducing Low-Density Lipoprotein Cholesterol
2014
Polycystic Ovary Syndrome
2005 Standout
Analysis of anticancer drugs: A review
2011 Standout
In Vitro Metabolism of Haloperidol and Sila-Haloperidol: New Metabolic Pathways Resulting from Carbon/Silicon Exchange
2009
Engineering and assaying of cytochrome P450 biocatalysts
2008
Zygomycosis (mucormycosis): emerging clinical importance and new treatments
2004
Prevention of Venous Thromboembolism
2008 Standout
Ezetimibe
2005
Pharmacokinetic/Pharmacodynamic Profile of Posaconazole
2010
Mesoporous Materials for Drug Delivery
2007 Standout
Investigating the in vitro metabolism of fipexide: characterization of reactive metabolites using liquid chromatography/mass spectrometry
2007
Treatment effects of eptifibatide in planned coronary stent implantation in patients with chronic kidney disease (ESPRIT Trial)
2003
Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): Comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes
2008
Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin
2001 Standout
Immunosuppressive Drugs for Kidney Transplantation
2004 Standout
Asymmetric Multicomponent Reactions (AMCRs): The New Frontier
2005 Standout
TRPV3 regulates nitric oxide synthase-independent nitric oxide synthesis in the skin
2011 StandoutNobel
Platelet-Active Drugs
2001
Platelet-Active Drugs: The Relationships Among Dose, Effectiveness, and Side Effects
2004
Influence of concurrent renal dysfunction on outcomes of patients with acute coronary syndromes and implications of the use of glycoprotein IIb/IIIa inhibitors
2003
Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with Neutropenia
2007 Standout
Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
2015 Standout
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial
2006 Standout
Kidney Disease as a Risk Factor for Development of Cardiovascular Disease
2003 Standout
3d Transition Metals for C–H Activation
2018 Standout
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Review of mechanisms and quantification of priming effects
2000 Standout
Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design
2018 Standout
2016 Infectious Diseases Society of America (IDSA) Clinical Practice Guideline for the Treatment of Coccidioidomycosis
2016 Standout
Degradation of citalopram by simulated sunlight
2005
Thymopentin in solid lipid nanoparticles
1996
Triazole antifungal agents drug–drug interactions involving hepatic cytochrome P450
2011
Human Pharmacogenomic Variations and Their Implications for Antifungal Efficacy
2006
Accessing Drug Metabolites via Transition‐Metal Catalyzed C−H Oxidation: The Liver as Synthetic Inspiration
2016
Guidelines for the Primary Prevention of Stroke
2014 Standout
ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease
2006 Standout
Posaconazole: A Next-Generation Triazole Antifungal
2007
Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America
2016 Standout
Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America
2015 Standout
Role of Prostacyclin in the Cardiovascular Response to Thromboxane A 2
2002 StandoutScience
Multicenter Study of Posaconazole Therapeutic Drug Monitoring: Exposure-Response Relationship and Factors Affecting Concentration
2012
Posaconazole Exposure-Response Relationship: Evaluating the Utility of Therapeutic Drug Monitoring
2012
Pharmaceuticals of Emerging Concern in Aquatic Systems: Chemistry, Occurrence, Effects, and Removal Methods
2019 Standout
Fluorescent Chemosensors Based on Spiroring-Opening of Xanthenes and Related Derivatives
2011 Standout
Applications of isotope dilution‐mass spectrometry in clinical chemistry, pharmacokinetics, and toxicology
1992
The Metabolic Syndrome
2008 Standout
Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative
2004
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
2016 Standout
Pharmacogenetics of Gilbert‘s Syndrome
2008
Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
2004 Standout
2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
2014 Standout
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention
2011 Standout
Structural Alert/Reactive Metabolite Concept as Applied in Medicinal Chemistry to Mitigate the Risk of Idiosyncratic Drug Toxicity: A Perspective Based on the Critical Examination of Trends in the Top 200 Drugs Marketed in the United States
2011
Effect of Oily Vehicles on Absorption of Mepitiostane by the Lymphatic System in Rats
1992
Synopsis of Some Recent Tactical Application of Bioisosteres in Drug Design
2011 Standout
Works of James E. Patrick being referenced
IDENTIFICATION OF HUMAN UDP-GLUCURONOSYLTRANSFERASE ENZYME(S) RESPONSIBLE FOR THE GLUCURONIDATION OF POSACONAZOLE (NOXAFIL)
2004
Comparative steady state bioavailability of conventional and controlled‐release formulations of albuterol
1987
IDENTIFICATION OF HUMAN UDP-GLUCURONOSYLTRANSFERASE ENZYME(S) RESPONSIBLE FOR THE GLUCURONIDATION OF EZETIMIBE (ZETIA)
2004
Disposition and pharmacokinetics of temozolomide in rat
2004
The Plasma Concentration and LDL-C Relationship in Patients Receiving Ezetimibe
2001
Disposition of 14C-eptifibatide after intravenous administration to healthy men
1998
Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin
2002
Stepwise determination of multicompartment disposition and absorption parameters from extravascular concentration-time data. Application to mesoridazine, flurbiprofen, flunarizine, labetalol, and diazepam
1991
Fragmentation of N‐oxides (deoxygenation) in atmospheric pressure ionization: Investigation of the activation process
2001
Rapid determination of enzyme activities of recombinant human cytochromes P450, human liver microsomes and hepatocytes
2003
Disposition of the Selective Cholesterol Absorption Inhibitor Ezetimibe in Healthy Male Subjects
2002
Comparative Bioavailability of a Lipophilic Steroid
1978
Quantitative analysis of albuterol in human plasma by combined gas chromatography chemical ionization mass spectrometry
1983
SHORT IN VITRO HALF‐LIFE OF THYMOPOIETIN 32–36 PENTAPEPTIDE IN HUMAN PLASMA
1979
Biotransformation of norgestimate in women
1984
Liquid Chromatography/Mass Spectrometry Methods for Distinguishing N-Oxides from Hydroxylated Compounds
2000
Comparative Bioavailability and Pharmacokinetics of Three Formulations of Albuterol
1985